Biomoda Inc. to Collaborate on Validation Study for Early Noninvasive Lung Cancer Diagnostic Testing.

ALBUQUERQUE, N.M. -- Mayo Clinic (Rochester, Minn.) and Biomoda Inc. (Albuquerque, N.M.) have agreed to jointly conduct a broad validation study of Biomoda's patented technology, a noninvasive cytology-based lung cancer diagnostic assay.

"The agreement between Mayo Validation Support Services and our company signals an essential step forward in Biomoda's commitment to developing and commercializing early noninvasive diagnostic tests for lung cancer," said Dr. Herbert Whitaker, exec. V.P. of Biomoda Inc.

"Mayo Clinic is one of the premier healthcare and research institutions in the world. Biomoda looks to derive very valuable benefits from this collaboration and we believe the time is now much nearer to when our lung cancer diagnostic test will be widely available," added John Cousins, president of Biomoda.

Lung cancer claims more lives than any other cancer. An estimated 162,460 deaths from lung cancer will occur in the United States during 2006, accounting for 29 percent of all cancer deaths this year. The expected five-year survival rate for all patients in whom lung cancer is diagnosed is 15 percent; and by contrast, the five-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

In early stages, the lung cancer patient usually does not exhibit symptoms. When symptoms manifest themselves, the cancer is often advanced. Biomoda's test offers the potential to reverse these statistics by providing early noninvasive detection for individuals who may not be aware that they have lung cancer. The test can be implemented in an automated environment, and has the potential to screen large populations in a cost-effective manner.

Biomoda Inc., a development stage in-vitro diagnostics company, is focused on research, development and commercialization of cancer diagnostics. The company has an intellectual property portfolio including patents and patents pending and will be enhancing its intellectual property position through additional patents pending and trademark registrations, both domestically and internationally. The company's proprietary technologies provide noninvasive and highly accurate approaches as cancer diagnostic products.

Operating from its laboratory at Kirtland Air Force Base (Albuquerque, N.M.), the company is in the process of expanding and expediting its product development and commercialization with a number of additional strategic alliances to be announced over the next 90 days.

About Mayo Validation Support Services

Mayo Validation Support Services, an affiliate of Mayo Clinic, based in Rochester, Minn., assists pharmaceutical, biotechnology and diagnostic companies in the preclinical validation of promising targets, lead compounds, biomarkers and tests. With a focus on the patient, Mayo Validation Support Services collaborates with organizations to help bring new diagnostic and therapeutic discoveries to people around the world.

This news release contains forward-looking statements that involve a high degree of risk and uncertainty. Such statements include, but are not limited to, statements containing the words "believes," "anticipates," "expects," "estimates," and words of similar import. The company's actual results could differ materially from any forward-looking statements, which reflect management's opinions only as of the date of this report, as a result of risks and uncertainties that exist in our operation, development efforts and business environment. The company undertakes no obligation to revise or publicly release the results of any revisions to these forward-looking statements. You should carefully review the risk factors in other documents that the company files from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q.